Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
Analiz edildi: 2026-05-08Sonraki güncelleme: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
Fiyat
$378.06
▼ -38.07 (-10.07%)
Gerçeğe uygun değer
$340
$340–$450
Tavsiye
Azalt
confidence 88/100
Yükseliş potansiyeli
-10.1%
upside to fair value
Güvenlik Marjı
$288.99
buy below · 15%
Piyasa Değeri
$343.3B
P/E fwd 18.2
İngilizce yedekTR
Çeviri yapılırken İngilizce kaynak gösteriliyor
Bu rapor henüz çevrilmedi. Çeviri kuyruğu yetiştiğinde birkaç dakika sonra sayfayı yenileyin.

§1 Yönetici özeti

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 Olumsuz senaryo

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

Bu tezin bozulabileceği yollar

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
İzlenecek erken uyarı sinyalleri
MetrikMevcutTetikleme eşiği
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 Mali geçmiş

Gelir tablosu — son altı dönem
KalemT−0T−1T−2T−3T−4CAGR
Dönem2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Gelir$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
Brüt kâr$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
Faaliyet kârı$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
Net kâr$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
EPS (sulandırılmış)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
R&D
SG&A

Kalite puanları

Piotroski F-skor
6 / 9
0–9 kalite bileşkesi
Altman Z-skor
2.97
İflas riski (>3 güvenli)
OCF / Net kâr
1.63×
>1 yüksek kazanç kalitesini gösterir
Muhasebe kalitesi kapısı
Pass
Sektöre göre ayarlanmış kapı
ROIC
8.6%
Yatırılan sermaye getirisi
Bölüm 3

Numbers analysis

Bireysel aboneler — §4 ve sonrası11 bölüm daha

Tam analizi okuyun — 11 bölüm daha.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Kapsanan her sembol için tam rapor
24 ay tavsiye arşivi
İzleme listesi brifingleri + tavsiye değişiklik uyarıları
Herhangi bir dilde PDF + DOCX dışa aktarma
Ücretsiz denemeyi başlat
İstediğin zaman iptal edebilirsin.
FAQ

UNH — frequently asked questions

  1. Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care